Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 15/20 | 0.54 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.52 |
| ▸ | PLA2G2F | Q9BZM2 | 1/20 | 0.52 |
| ▸ | PLA2G2E | Q9NZK7 | 1/20 | 0.52 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862552 | 1.00 | PLA2G2A (0.54) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2F | |
| SCHEMBL818168 | 0.90 | PLA2G2A (0.44) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2F | |
| SCHEMBL6695139 | 0.89 | PLA2G2A (0.51) | PLA2G2APLA2G10 | |
| SCHEMBL2595689 | 0.89 | PLA2G2A (0.66) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2F | |
| SCHEMBL6129648 | 0.86 | PLA2G2A (0.46) | PLA2G2APLA2G10 | |
| SCHEMBL29862616 | 0.85 | PLA2G2A (0.52) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2F | |
| SCHEMBL818181 | 0.85 | PLA2G2A (0.52) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2F | |
| SCHEMBL6693386 | 0.84 | PLA2G2A (0.51) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2F | |
| SCHEMBL6693400 | 0.84 | PLA2G2A (0.51) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2F | |
| SCHEMBL6692869 | 0.84 | PLA2G2A (0.44) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1011670-A4 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | LILLY CO ELI (US) | 2004-10-27 | — | — | EP | claimed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | claimed |
| EP-0839806-B1 | Substituted tricyclics | LILLY CO ELI (US) | 2003-07-09 | — | — | EP | claimed |
| US-6514984-B1 | Human non-pancreatic secretory phospholipase A2 inhibitors | ELI LILLY AND COMPANY | 2003-02-04 | — | — | US | claimed |
| EP-1214041-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2000037022-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| EP-1011670-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 2000-06-28 | — | — | EP | claimed |
| EP-1007056-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | claimed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1998018464-A1 | SUBSTITUTED TRICYCLICS | ELI LILLY AND COMPANY (US) | 1998-05-07 | — | — | WO | claimed |
| CN-107249578-B | Method for treating envenomation and related pharmaceutical composition, system and kit | 奥菲瑞克斯股份有限公司 | 2021-01-26 | — | — | CN | disclosed |
| WO-2013067579-A1 | ADIPOSITY-MODULATING MOLECULES AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-05-16 | — | — | WO | disclosed |
| US-20110301202-A1 | SPLA2 INHIBITOR CONJUGATE COMPOUNDS AND METHODS OF USE | ANTHERA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| WO-2011137390-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-6514984-B1 | Human non-pancreatic secretory phospholipase A2 inhibitors | ELI LILLY AND COMPANY | 2003-02-04 | — | — | US | disclosed |
| EP-1011670-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-1007056-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301202-A1 | SPLA2 INHIBITOR CONJUGATE COMPOUNDS AND METHODS OF USE | PCSK9, PCSK6, NAPRT | PLA2G2A 47/4885PLA2G10 74/4885PLA2G1B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.